Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir Dose-Ranging Study in Treatment-Naïve Chronic Hepatitis C
NCT01710501Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of grazoprevir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response at 12 Weeks After End of Treatment, Participants Experiencing at Least One Adverse Event up to 26 weeks and 1 more. Started Dec 2012; status: completed.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01710501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710501.